[Hematopoietic growth factors in oncology and hematology. Recommendations for more cost-efficient use].
Paul
C
C
Hematologiska kliniken, Huddinge sjukhus, Stockholm.
Hast
R
R
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D016179:Granulocyte Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000188:drug therapy* / Q000191:economics; D016298:Hematopoietic Cell Growth Factors / Q000191:economics / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics; D009503:Neutropenia / Q000188:drug therapy / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D013548:Sweden
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor